Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) | MicrobiomeTrials
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2021-05-03Est. Completion: 2026-07-01
Enrollment target: 48 participants
Locations
City of Hope Comprehensive Cancer Center, Duarte, California, United States
City of Hope at Irvine Lennar, Irvine, California, United States
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
Northwestern University, Chicago, Illinois, United States
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Washington University School of Medicine, St Louis, Missouri, United States
Siteman Cancer Center-South County, St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Other microbiome trials you might be interested in